Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01133665 · ClinicalTrials.gov registry record · Phase 2
Cetuximab and Lenalidomide in Head and Neck
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01133665 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 42 participants.
The verdict
NCT01133665, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to study specific FcRIIIa polymorphisms and their correlation with clinical outcome in subjects treated with cetuximab and lenalidomide.
Interventions
- DRUG Cetuximab and Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01133665
The ClinicalTrials.gov registry entry for NCT01133665 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cetuximab and Lenalidomide is the first listed.
NCT01133665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01133665 about?
NCT01133665 is a clinical study titled "Cetuximab and Lenalidomide in Head and Neck". The purpose of this study is to study specific FcRIIIa polymorphisms and their correlation with clinical outcome in subjects treated with cetuximab and lenalidomide.
What is the current status of trial NCT01133665?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2010-02. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01133665?
The interventions under investigation include: Cetuximab and Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01133665?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.